Allarity Therapeutics Secures First Lab Services Contract With European Biotech Company
Bitget2026/10/30 11:45- Allarity Therapeutics secured its first revenue-generating contract under its CLIA-certified laboratory services strategy with a European biotechnology company.
- The agreement covers development and validation services for a precision oncology predictive device intended for US use.
- Successful completion could lead to recurring commercial testing and CLIA-related service revenue.
- Stenoparib remains its top development priority.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Asia-Pacific stock markets follow the overnight rally in US tech stocks, with South Korea's KOSPI up 5% at the open, SK Hynix surging more than 7%, and Nikkei 225 rising over 2%.
This round of rebound occurred after the market experienced severe turbulence. Last week, concerns over the potential for stricter regulation of the artificial intelligence industry, due to the US Congressional election results, triggered a large-scale sell-off in chip stocks. Several market participants believe that this rebound indicates investors have not abandoned the AI trading narrative, and last week’s sell-off was more about position adjustments rather than a trend reversal.
Barrick’s Marquee gold project faces hazy study timing
Japanese and South Korean stock markets open
Marvell Technology (MRVL.US) $115 billion "merger of the century" faces lukewarm reception! Stock has dropped over 40%, experts estimate only a 50% chance of completion
Marvell plans to acquire Lamington for 115 billions USD to strengthen its position in AI, but the probability of completion is only 50%. The two stocks have dropped by nearly 40% and about 35% respectively, with Chinese regulatory approval being the biggest uncertainty.
Crypto prices
More
